Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 50 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Results available

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454
Conditions
Psychosis
Interventions
Omega-3 Long Chain Fatty Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 30 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Examine the Effects of Oral Fenretinide

NCT06528457
Conditions
Dengue
Interventions
ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo
Drug · Other
Lead sponsor
Island Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Syracuse, New York
Completed Phase 3 Interventional Results available

SGA-induced Metabolic Syndrome in Bipolar Youth

NCT01858948
Conditions
Bipolar Youth Treated With Second-generation Antipsychotics
Interventions
Omega, Placebo, Quetiapine fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Not applicable Interventional Accepts healthy volunteers

The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial

NCT00835289
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
n-3 polyunsaturated fatty acids, Placebo
Dietary Supplement · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Overweight and Obesity, Insulin Resistance, Diabetes, Gestational, Hypertension in Pregnancy, Pre-Eclampsia
Interventions
DHA Supplements, Placebo Supplements
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions
Omega-3 fatty acid administration, Placebo
Drug
Lead sponsor
Brown, Todd, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Chronic Pain Following Thermal Burn Injury
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Autism
Interventions
docosahexaenoic acid (DHA), Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 10 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Eldery People, Cognitive Decline, Memory Decline, DHA CNS Delivery
Interventions
LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 82 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 2Phase 3 Interventional Results available

Fish Oil Study for High Triglyceride Levels in Children

NCT00915902
Conditions
Hypertriglyceridemia
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Babu Balagopal
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Conditions
Liver Disease, Short Bowel Syndrome
Interventions
Lovaza (omega-3-acid ethyl ester), Corn oil
Drug · Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Results available

Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease

NCT00090402
Conditions
Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia, Inflammation
Interventions
Fish Oil, Lipoic Acid, Fish Oil Placebo, Lipoic Acid Placebo
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
21 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Results available

Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome

NCT01107964
Conditions
Dry Eye Syndrome
Interventions
Oral Omega-3-acid ethyl esters, Placebo corn oil capsule
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
AKBM-3031, Placebo
Dietary Supplement · Other
Lead sponsor
Aker BioMarine Human Ingredients AS
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
Terminated Phase 1Phase 2 Interventional Results available

The Effects of Lovaza® in Acute Myocardial Infarction

NCT01155336
Conditions
Myocardial Infarction
Interventions
Lovaza®, The placebo contained 1 gram of corn oil in each capsule.
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Garden Grove, California • Los Angeles, California + 8 more
Conditions
Depression
Interventions
2:1 EPA/DHA, High EPA, Placebo
Drug · Other
Lead sponsor
Wei Jiang
Other
Eligibility
21 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania
Conditions
Covid19
Interventions
TQ Formula/Tab
Drug
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Diego, California • Hialeah, Florida • Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Heart & Health Study

NCT00536185
Conditions
Heart Disease
Interventions
Fish Oil, Placebo
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
20 Years to 59 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
3
States / cities
Davis, California • Oakland, California • Sacramento, California
Completed Not applicable Interventional Results available

Omega-3 Dietary Supplements in Schizophrenia

NCT01786239
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions
Risperidone, Omega-3 capsules, Placebo
Drug
Lead sponsor
Delbert Robinson
Other
Eligibility
15 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York